Aclaris Therapeutics, Inc. (ACRS) Stock Price & Analysis
Aclaris Therapeutics, Inc. (ACRS) closed at USD 3.99 on Thursday, October 29, 2026, up 0.76% on the day. The US market is currently closed (after-hours); this is not a live price.
The prior close was USD 3.96; the Oct 29, 2026 session ranged USD 3.96–4.08 on volume of 1,457,188 shares. Market capitalization is $587.32M, with a 52-week range of USD 2.1–6.6 (NMS). Source: Nexqual, retrieved October 29, 2026 at 21:32 UTC.
Also available as compact Markdown for AI agents: nexqual.com/ACRS.md
Key facts (ACRS)
- Last four reported quarters (through Jun 30, 2026): revenue $8.2M, net income -$75.7M (-921.5% margin), free cash flow -$62.2M (SEC filings).
- Insider open-market sales, last ~7 months: 1 Form 4 filings, $1.4M; 1 not under a Rule 10b5-1 plan ($1.4M); 0 by opportunistic insiders, 0 by routine insiders (three-year test, Cohen, Malloy & Pomorski 2012).
- Analysts: Buy (mean 2.00 on a 1–5 scale) (12 analysts), mean target USD 10.09 (range 4–16).
- Total return with dividends: 1Y +60.2% vs S&P 500 +14.4%; 5Y -77.0% vs S&P 500 +79.1%.
- Next earnings: 2026-11-05, EPS estimate USD -0.16, revenue estimate $1.2M.
Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (ACRS)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $6.8M | $29.8M | $31.2M | $18.7M | $7.8M | $8.2M |
| Gross profit | $2.0M | $25.7M | $27.8M | $15.9M | $5.7M | — |
| Operating income | -$89.7M | -$89.9M | -$97.4M | -$142M | -$76.4M | -$86.3M |
| Net income | -$90.9M | -$86.9M | -$88.5M | -$132M | -$64.9M | -$75.7M |
| EPS (diluted) | -$1.60 | -$1.33 | -$1.27 | -$1.71 | -$0.53 | — |
| Free cash flow | -$52.4M | -$68.2M | -$79.6M | -$20.2M | -$47.2M | -$62.2M |
| Gross margin | 30.3% | 86.5% | 89.0% | 85.1% | 73.3% | — |
| Operating margin | -1327.1% | -302.0% | -311.6% | -758.2% | -975.9% | -1050.2% |
| Net margin | -1344.0% | -292.1% | -283.1% | -705.5% | -829.6% | -921.5% |
| Revenue growth | +4.3% | +340.1% | +5.0% | -40.1% | -58.2% | — |
| Cash + short-term investments | $226M | $230M | $182M | $204M | $151M | — |
Fiscal years end Dec. EPS is split-adjusted.
Valuation (price ÷ last four quarters, through Jun 30, 2026) (ACRS)
P/S 71.5x · P/B 4.7x · FCF yield -10.59% · Earnings yield -12.90%
Insider sales (SEC Form 4, open-market, last ~7 months) (ACRS)
0 of 1 under a Rule 10b5-1 trading plan (scheduled in advance). Unplanned sales were timed by the insider.
| Trade date | Insider | Role | Shares | Value | % of holdings sold | 10b5-1 plan | Insider type |
|---|---|---|---|---|---|---|---|
| 2026-04-23 | Leonard Braden Michael | 300,000 | $1.4M | 2.1% | No | Too little history (no open-market trades in 2023 or 2025) |
% of holdings sold = shares sold ÷ (shares sold + all holdings the insider reported on that Form 4, direct and through trusts).
Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.
Analysts (ACRS)
Consensus Buy (mean 2.00 on a 1–5 scale), 12 analysts; mean target USD 10.09 (low 4, high 16).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-28 | Wedbush | Target lowered | Outperform | $10 → $8 |
| 2026-10-28 | HC Wainwright & Co. | Reiterated | Buy | $16 |
| 2026-09-01 | Canaccord Genuity | Initiated | Buy | $10 |
Total return (dividends reinvested) (ACRS)
| 1Y (from 2025-10-30) | 5Y (from 2021-10-25) | |
|---|---|---|
| Total return | +60.2% | -77.0% |
| S&P 500 (SPY) | +14.4% | +79.1% |
| Per year | +60.5% | -25.4% |
| Volatility (annualized) | 88.1% | 106.3% |
| Max drawdown | -49.8% (Aug 2026→Oct 2026) | -95.4% (Nov 2022→Nov 2023) |
ACRS earnings history and stock reaction
| Results filed | Quarter | EPS | Consensus | Surprise | Stock reaction |
|---|---|---|---|---|---|
| Oct 27, 2026 | — | — | — | — | +4.5% |
| Aug 6, 2026 | Quarter ended Jun 30, 2026 | −$0.15 | −$0.16 | Beat +6.3% | -7.1% |
| May 7, 2026 | Quarter ended Mar 31, 2026 | −$0.15 | −$0.16 | Beat +6.3% | +3.1% |
| Feb 26, 2026 | Quarter ended Dec 31, 2025 | −$0.16 | −$0.14 | Miss −14.3% | -13.3% |
| Nov 6, 2025 | Quarter ended Sep 30, 2025 | −$0.12 | −$0.14 | Beat +14.3% | +2.7% |
| Aug 7, 2025 | — | — | — | — | +5.2% |
| May 8, 2025 | — | — | — | — | +0.8% |
| Feb 27, 2025 | — | — | — | — | -5.2% |
EPS as reported against the analyst consensus before the release; surprise uses the cent-rounded figures shown (in dollars when EPS and consensus have opposite signs). Stock reaction = close before the results to close after (the first close following a release after the bell or before the open).
ACRS recent SEC filings (last 120 days)
| Filed | Form | What it says |
|---|---|---|
| Oct 27, 2026 | 8-K | Entered a material agreement “On October 27, 2026, Aclaris Therapeutics, Inc. (the "Company") entered into an underwriting agreement (the "Underwriting Agreement") with Leerink Partners LLC, Piper Sandler & Co. and Cantor Fitzgerald & Co., as representatives of the underwriters (the "Underwriters") listed therein, to issue and sell 7,785,714 shares of common stock of the Company, par value $0.00001 per share ("Common Stock") and pre-funded warrants to purchase 6,500,000 shares of Common Stock (the "Pre-Funded Warrants"), in an underwritten…” |
| Oct 27, 2026 | 8-K | Quarterly results; Regulation FD disclosure; Other material event “Cash, Cash Equivalents and Marketable Securities as of September 30, 2026 Based upon preliminary estimates and information available to the Company, it estimates that its cash, cash equivalents and marketable securities were approximately $204.6 million as of September 30, 2026. This amount has not been audited, reviewed, or compiled by the Company's independent registered public accounting firm. The Company's actual cash, cash equivalents and marketable securities as of September 30, 2026 may differ from this…” |
| Sep 21, 2026 | Schedule 13G | Frazier Life Sciences Public Fund, L.P., FHMLSP, L.P.: 5.4% of shares, passive 5%+ holder |
| Aug 14, 2026 | Schedule 13G/A | RA Capital Management, L.P., Peter Kolchinsky: 9.1% of shares, passive 5%+ holder (amended) |
| Aug 6, 2026 | 8-K | Entered a material agreement “On August 6, 2026, Aclaris Therapeutics, Inc. (the "Company") entered into a Second Amended and Restated Sales Agreement (the "Amended ATM Agreement") with Leerink Partners LLC ("Leerink") and Cantor Fitzgerald & Co. ("Cantor") under which the Company may offer and sell, from time to time at the Company's sole discretion, shares of common stock through Leerink and Cantor as sales agents. The issuance and sale, if any, of common stock under the Amended ATM Agreement will be made pursuant to a registration statement…” |
| Aug 6, 2026 | 10-Q | Quarterly report · period ended Jun 30, 2026 |
| Aug 6, 2026 | 8-K | Quarterly results |
Source: SEC EDGAR. Quotes are the opening words of each item as filed; each form links to the filing. Insider Form 4 filings are listed in the insider sections.
ACRS revenue by product line (quarter ended Jun 30, 2026)
| Line | Revenue | Share of total | YoY |
|---|---|---|---|
| License & Service | $1.3M | 78.1% | -4.6% |
| Dermatology Therapeutics | $1.3M | 78.1% | -4.6% |
| Laboratory Research Revenue | $356,000 | 21.9% | -19.5% |
| Contract Research | $356,000 | 21.9% | -19.5% |
| Total revenue | $1.6M | 100% | — |
As tagged by the company in its SEC 10-Q / 10-K filings (XBRL).
ACRS suppliers, customers and competitors (named in its 10-K)
| Relationship | Company | Sentence in the filing |
|---|---|---|
| Partner | Eli Lilly (LLY) | “Under the royalty purchase agreement, we sold to OMERS a portion of the future royalty payments and the remaining anniversary payments associated with our existing license to Eli Lilly and Company ("Lilly"), relating to OLUMIANT® (baricitinib) for the treatment of alopecia areata (see "—License Agreement with Eli Lilly and Company").” |
| Partner | Biosion | “In November 2024, we entered into an exclusive license agreement (the "Biosion Agreement") with Biosion, pursuant to which we received exclusive rights to develop, manufacture and commercialize bosakitug and ATI-052 worldwide, excluding Greater China.” |
| Partner | Chia Tai Tianqing Pharmaceutical Group | “In connection with the Biosion Agreement, we also entered into a collaboration agreement (the "CTTQ Agreement", and together with the Biosion Agreement, the "Biosion Agreements") with Biosion and CTTQ, a licensee of bosakitug in Greater China.” |
| Partner | WuXi | “If WuXi or our other partners are designated as BCCs, we” |
| Partner | Sun Pharmaceutical Industries | “In December 2023, we entered into an exclusive patent license agreement with Sun Pharmaceutical Industries, Inc. ("Sun Pharma").” |
| Partner | Pediatrix Therapeutics | “In November 2022, we entered into a license agreement with Pediatrix Therapeutics, Inc. ("Pediatrix") under which we granted Pediatrix the exclusive rights to develop, manufacture and commercialize lepzacitinib in Greater China.” |
| Partner | EPI Health | “Through the bankruptcy process, EPI Health and its parent company, Novan, Inc., sold the RHOFADE assets to a third party, which excluded our asset purchase agreement with EPI Health and the outstanding amounts due.” |
| Partner | Novan | “Through the bankruptcy process, EPI Health and its parent company, Novan, Inc., sold the RHOFADE assets to a third party, which excluded our asset purchase agreement with EPI Health and the outstanding amounts due.” |
| Competitor | Pfizer (PFE) | “With respect to ATI-052, our primary competitors include those developing multi-specific antibodies designed to inhibit both TSLP and IL-4Rα activity, such as Innovent Biologics (IBI3002) and Pfizer (PF-07275315).” |
| Competitor | AbbVie (ABBV) | “In addition, several companies are developing or have commercialized JAK inhibitors that may compete with ATI-2138, if approved, including Pfizer (tofacitinib, abrocitinib, and ritlecitinib), Eli Lilly (baricitinib), AbbVie (upadacitinib), and Sun Pharmaceutical (deuruxolitinib).” |
Quoted from the company's 10-K filed Feb 26, 2026.
ACRS company outlook (results filed Oct 27, 2026)
- “Any forward-looking statements speak only as of the date of this press release and are based on information available to Aclaris as of the date of this release, and Aclaris assumes no obligation to, and does not intend to, update any forward-looking statements, whether as a result of new information, future events or otherwise.”
Quoted word-for-word from the SEC 8-K results press release.
ACRS analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Sep 2026) | $-0.16 | $-0.17 | +$0.01 | $1.2M | 11 |
| Next quarter (ends Dec 2026) | $-0.18 | $-0.17 | −$0.01 | $1.3M | 11 |
| Current fiscal year (ends Dec 2026) | $-0.64 | $-0.66 | +$0.01 | $6.2M | 11 |
| Next fiscal year (ends Dec 2027) | $-0.74 | $-0.83 | +$0.09 | $5.3M | 11 |
ACRS options: expected move
Options price a move of about ±31.0% (±$1.20) by Nov 20, 2026, which includes earnings on Nov 5, 2026. Over the last 8 reports the stock moved ±5.2% on average.
| Expiration | Days | ATM implied volatility | Expected move |
|---|---|---|---|
| Nov 20, 2026 | 22 | 151.4% | ±31.0% |
| Dec 18, 2026 | 50 | 82.6% | ±28.4% |
| Jan 15, 2027 | 78 | 152.8% | ±25.6% |
| Feb 19, 2027 | 113 | 101.9% | ±45.9% |
| Mar 19, 2027 | 141 | 99.9% | ±50.4% |
| May 21, 2027 | 204 | 119.2% | ±69.8% |
30-day implied volatility 113.7% vs 96% realized over the last 30 trading days. Put/call ratio (volume) 0. Cboe delayed quotes (15 min). Expected move = at-the-money straddle.
Key Statistics (as of October 29, 2026 at 21:32 UTC)
| Price | USD 3.99 |
|---|---|
| Change | ▲ 0.76% (up) |
| Previous Close | USD 3.96 |
| Open | USD 4.05 |
| Day Range | USD 3.96 – 4.08 |
| 52-Week Range | USD 2.1 – 6.6 |
| Volume | 1,457,188 shares |
| Market Cap | $587.32M |
| Exchange | NMS |
Technical Analysis (ACRS)
Nexqual's technical model rates ACRS "SELL" based on 2 bullish and 4 bearish signals across 127 daily candles, as of October 29, 2026 at 21:32 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 45.13 (neutral) |
| vs SMA50 | Below (USD 4.93) |
| MACD | -0.28 (negative) |
Analyst Ratings (ACRS)
Wall Street analysts rate ACRS "Buy" based on 12 analysts, with a mean price target of USD 10.09 (range USD 4–16), per Nexqual as of October 29, 2026 at 21:32 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 12 |
| Mean Target | USD 10.09 |
| High Target | USD 16 |
| Low Target | USD 4 |
| Buy / Hold / Sell | 11 / 1 / 0 |
Earnings (ACRS)
| Next Earnings Date | 2026-11-05 |
|---|---|
| EPS Estimate | USD -0.16 |
| Revenue Estimate | $1.23M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD -0.15 vs est -0.16 ▲ beat |
| 2026-03-31 | USD -0.15 vs est -0.16 ▲ beat |
| 2025-12-31 | USD -0.16 vs est -0.14 ▼ miss |
| 2025-09-30 | USD -0.12 vs est -0.14 ▲ beat |
Source: Nexqual, October 29, 2026 at 21:32 UTC.
Financials & Fundamentals (ACRS)
| Total Revenue | $8.22M |
|---|---|
| Revenue Growth (latest quarter, YoY) | -8.30% |
| Gross Margin | +0.00% |
| Operating Margin | -1469.49% |
| Profit Margin | +0.00% |
| ROE | -59.10% |
| Debt / Equity | 0.01 |
| Current Ratio | 3.46 |
| Total Cash | $91.56M |
| Total Debt | $1.85M |
| Free Cash Flow (last four quarters to Jun 2026, SEC 10-Q / 10-K) | -$62.18M (-756.5% of revenue) |
Source: Nexqual, October 29, 2026 at 21:32 UTC.
Financial Health Score (ACRS)
Nexqual rates Aclaris Therapeutics, Inc.'s overall financial health "Weak" across five dimensions, as of October 29, 2026 at 21:32 UTC.
| Growth | Critical — Revenue -58% YoY (annual), sharp decline |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Strong — $92M cash vs $2M debt, net cash position |
| Cash Flow | Weak — FCF negative: -$62M (last 4 quarters to Jun 2026, SEC), burning cash |
| Efficiency | Critical — ROE -61%, ROA -42.1% (last 4 quarters, SEC) |
Ownership (ACRS)
| Insider Ownership | +2.18% |
|---|---|
| Institutional Ownership | +83.78% |
| Shares Outstanding | 147.20M |
| Float | 101.17M |
| Short % of Float | +11.59% |
Source: Nexqual, October 29, 2026 at 21:32 UTC.
Leadership (ACRS)
Aclaris Therapeutics, Inc. is led by Neal S. Walker D.O., Co-Founder, CEO & Chairman, per Nexqual as of October 29, 2026 at 21:32 UTC.
| Co-Founder, CEO & Chairman | Neal S. Walker D.O. |
|---|---|
| President, COO & Director | Hugh M. Davis |
| Chief Financial Officer | Kevin Balthaser |
| Chief Scientific Officer | Roland Kolbeck |
| Senior Vice President of Corporate Communications & Investor Relations | William C. Roberts |
Major Backers & Investors (ACRS)
Notable institutional backers of Aclaris Therapeutics, Inc. include RA Capital Management, L.P., BML Capital Management, LLC, Deep Track Capital, Lp, according to Nexqual as of October 29, 2026 at 21:32 UTC.
Active Investors
| Investor | Stake |
|---|---|
| RA Capital Management, L.P. | 9.1% |
| BML Capital Management, LLC | 8.56% |
| Deep Track Capital, Lp | 6.68% |
| Vivo Capital, LLC | 4.79% |
| Frazier Life Sciences Management, L.P. | 3.52% |
| Fidelity | 3.35% |
| Rock Springs Capital Management, LP | 3.1% |
| Adage Capital Partners GP L.L.C. | 2.91% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 7.18% |
| Vanguard Group | 4.16% |
Source: Nexqual, October 29, 2026 at 21:32 UTC.
From Aclaris Therapeutics, Inc.'s Latest SEC 10-K Filing (filed 2026-02-26)
Key Strengths & Strategy (as disclosed to the SEC)
- Our proprietary KINect drug discovery platform coupled with our integrated discovery approach to small and large molecules enables us to identify and advance product candidates designed to have superior target affinity, specificity and potency.
- Our KINect platform allows us to address challenges associated with difficult to drug kinases including selectivity and biochemical efficiency, through a unique combination of our proprietary chemical library of kinase inhibitors, our novel approaches to inhibitor modalities, our expertise in SBDD, and our custom kinase assays.
- In the United States, the FDA regulates drugs under the Federal Food, Drug, and Cosmetic Act ("FDCA") and its implementing regulations, and biologics under the FDCA, the Public Health Service Act ("PHSA") and their implementing regulations.
- We conduct small molecule drug discovery through KINect, our proprietary drug discovery platform.
Partnerships
- In connection with the Biosion Agreement, we also entered into a collaboration agreement (the "CTTQ Agreement", and together with the Biosion Agreement, the "Biosion Agreements") with Biosion and CTTQ, a licensee of bosakitug in Greater China.
- Under the Confluence Agreement, we agreed to pay the former Confluence equity holders aggregate remaining contingent consideration of up to $75.0 million based upon the achievement of specified regulatory and commercial milestones set forth in the Confluence Agreement.
Legal & Regulatory Risks (Item 1A, quoted)
- Any product candidate for which our potential third-party partners obtain marketing approval could be subject to post-marketing restrictions or recall or withdrawal from the market, and our potential third-party partners may be subject to penalties if they fail to comply with regulatory requirements or if they experience unanticipated problems with our product candidates, when and if any of them are approved.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| KOD | Kodiak Sciences Inc | USD 100.4 | ▲ 3.46% |
| RYTM | Rhythm Pharmaceuticals, Inc. | USD 93.07 | ▲ 1.2% |
| ORKA | Oruka Therapeutics, Inc. | USD 96.65 | ▲ 0.71% |
| AXSM | Axsome Therapeutics, Inc. | USD 143.45 | ▼ 0.04% |
| IONS | Ionis Pharmaceuticals, Inc. | USD 44.39 | ▼ 1.14% |
| ABVX | Abivax SA | USD 89.06 | ▼ 0.87% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 29, 2026 at 21:32 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt